Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SEER 
Seer Inc (SEER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SEER (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.45% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 124.51M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 3 | Beta 1.59 | 52 Weeks Range 1.62 - 2.62 | Updated Date 10/15/2025 |
52 Weeks Range 1.62 - 2.62 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -506.79% |
Management Effectiveness
Return on Assets (TTM) -15.27% | Return on Equity (TTM) -25.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -60485062 | Price to Sales(TTM) 7.64 |
Enterprise Value -60485062 | Price to Sales(TTM) 7.64 | ||
Enterprise Value to Revenue 0.11 | Enterprise Value to EBITDA 1.72 | Shares Outstanding 52294370 | Shares Floating 40279247 |
Shares Outstanding 52294370 | Shares Floating 40279247 | ||
Percent Insiders 3.39 | Percent Institutions 65.42 |
Upturn AI SWOT
Seer Inc
Company Overview
History and Background
Seer, Inc. (SEER) was founded in 2017 and is focused on developing products for proteomics research to enable better understanding of biology and disease.
Core Business Areas
- Proteogenomic Analysis: Offers a proprietary Proteograph Product Suite, including consumables and instruments, enabling deep unbiased proteomic profiling to unlock insights into health and disease.
Leadership and Structure
Omead Ostadan serves as the CEO. The company has a typical structure for a biotech firm, with departments focused on research, product development, sales, and operations.
Top Products and Market Share
Key Offerings
- Proteograph Product Suite: The core offering, consisting of Proteograph Consumables (nanoparticles) and Instruments, enable comprehensive proteomic profiling. It is difficult to estimate exact market share as the market is emerging. Competitors include companies developing mass spectrometry-based proteomics solutions (e.g., Thermo Fisher Scientific, Agilent Technologies, Bruker) and targeted proteomics companies.
Market Dynamics
Industry Overview
The proteomics market is growing rapidly, driven by increasing demand for personalized medicine and advancements in technologies that enable deeper proteomic analysis.
Positioning
Seer is positioned as a leading innovator in unbiased proteomic analysis with its Proteograph technology, competing with both targeted and other untargeted proteomics approaches. Their Proteograph platform aims to improve the scale, accuracy and speed of proteomic analysis.
Total Addressable Market (TAM)
The proteomics market is projected to reach billions of dollars. Seer aims to capture a significant portion of the research and clinical applications within this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary Proteograph technology
- Early mover advantage in unbiased proteomics
- Strong intellectual property portfolio
Weaknesses
- Relatively new company with limited track record
- Dependence on adoption of Proteograph technology
- High cost of Proteograph system
Opportunities
- Growing proteomics market
- Partnerships with pharmaceutical companies
- Expansion into clinical applications
Threats
- Competition from established players in proteomics
- Technological advancements from competitors
- Regulatory hurdles for clinical applications
Competitors and Market Share
Key Competitors
- TMO
- DHR
- AGIL
Competitive Landscape
Seer's advantage lies in its unique Proteograph technology. Disadvantages include it being a young company competing against much larger and established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth needs to be updated using latest financial information.
Future Projections: Analyst projections suggest continued revenue growth contingent on further adoption of the Proteograph platform.
Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts, forming partnerships with academic institutions, and developing new applications for the Proteograph technology.
Summary
Seer Inc is an early-stage proteomics company with promising Proteograph technology, but it faces challenges in a competitive market. Its revenue relies on the technology's adoption, which is still low. While it has a strong intellectual property portfolio, it also requires significant investment. Its financial health hinges on effective sales, partnerships, and successful clinical applications.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Seer Inc. Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Financial data may be outdated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Seer Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-12-04 | Founder, CEO, & Chair of the Board of Directors Dr. Omid C. Farokhzad M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 134 | Website https://seer.bio |
Full time employees 134 | Website https://seer.bio | ||
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.